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costs across hernia repair and mesh type cohorts are also presented. RESULTS:
Across treatment groups the majority of patients were white (70%) with a mean
age of 54 years. Inguinal and umbilical hernia repair groups were both predomi-
nantly male with low to moderate incidences of obesity and diabetes. Incisional
hernia repair patients had the highest incidence of obesity (19.0%) and diabetes
(18.5%) and could be equally either male (42.0%) or female (58.0%). Tissue-separat-
ing mesh (TSM) was used mainly in incisional hernia repairs, whilst other meshes
were used in all surgical cohorts. TSM was used more frequently in females (60.1%)
and in patients with a high incidence of obesity (22.7%) and diabetes (22.1%). No
striking differences in surgical costs across the hernia repair or mesh type cohorts
were observed, with average surgical costs between $2199 and $4099.
CONCLUSIONS: This is the first example of extracting hernia repair patient demo-
graphics from a nationwide database. Although there are limitations to the inter-
pretation of this data, these results are encouraging. Further development of the
management, analysis and interpretation of such data is ongoing.
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DECISION ANALYTIC MODELS USED IN ESTIMATING THE COST-
EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS
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OBJECTIVES: Drug-eluting stents (DES) and bare-metal stents (BMS) are both used
widely in percutaneous coronary interventions (PCI). However, the incremental
cost-effectiveness of DES versus BMS varies considerably between studies. A sys-
tematic review is performed to gain insight how modeling influences the cost-
effectiveness of DES versus BMS. METHODS: We reviewed modeling studies pub-
lished until February 2011 that studied the cost-effectiveness of DES versus BMS.
We then extracted various parameters (e.g., model type, time horizon, data
sources, choice of disease states) and explored the influence of these parameters
on the cost-effectiveness outcomes. RESULTS: The incremental cost-effectiveness
ratios (ICER) from the 22 eligible studies ranged from DES being dominated by BMS
to DES being dominant. Different parameters can contribute to these differences,
including time horizon, assumptions concerning stent efficacy, study perspective,
stent cost prices and the specific type of stents being compared. Almost half of the
studies used a time horizon 12 months, assuming that differences in clinical
events between the two stents occur in the first year. However, published literature
contradicts this assumption since DES can induce very late in-stent thrombosis.
Moreover, many studies base restenosis rates on angiographic follow-up. Since
angiography overestimates the difference in restenosis rate between DES and BMS,
its use leads to an overestimate of quality-adjusted life-years gained and number of
avoided reinterventions and an underestimate of the costs of the DES strategy. The
price premium of DES versus BMS differs considerably between studies (€900-
€3300) and this difference also affects the ICER. CONCLUSIONS: Choices made in
cost-effectiveness models to compare DES with BMS lead to wide variation in cost-
effectiveness estimates, making it difficult to conclude that DES is more cost-effec-
tive than BMS. Since 80,000 PCIs are performed per year in the UK, it is very impor-
tant to obtain valid estimates of the cost-effectiveness of DES versus BMS.
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DRUG ELUTING BALLOON FOR THE TREATMENT OF PERIPHERAL ARTERY
DISEASE: A COST-EFFECTIVENESS ANALYSIS IN ITALY
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OBJECTIVES: Conventional balloon angioplasty for treatment of femoropopliteal
arterial disease is associated with a high restenosis rates 12 months post-proce-
dure. Recent clinical data have showed that use of DEBs may substantially reduce
restenosis. This suggests that DEB may decrease number of revascularizations and
therefore be a cost-effectiveness treatment for peripheral artery disease (PAD).
This study evaluated the economic impact of using a drug-eluting balloon (DEB) for
treatment of femoropoliteal arterial disease. METHODS: A decisional tree model
has been developed to compare two alternative treatment strategies for superficial
femoral artery disease (SFA): standard balloon angioplasty (PTA) and provisional
stenting versus DEB. Cost for initial hospital care and the long term management of
the disease, including reintervention, has been accounted for according to National
Health Care Service and societal perspectives. Probabilities have been retrieved by
available literature review of RCT and from an observational study on DEB that
evaluated risk of target lesion revascularization (TLR) at 1 year. Uncertainty around
the model inputs was tested using unvaried and multivariate sensitivity analyses
RESULTS: Specific procedure costs (including angioplasty balloon, DEB, stent, con-
trast medium) were 1500€ in both group because incremental cost for use of DEB
was offset by reduction of number of stents used in the DEB arm. No difference has
been noted also for initial hospitalization. Given a 1 year TLR rate of 8.7% and 14%
for DEB and stenting respectively, DEB resulted a cost-saving strategy for the treat-
ment of superficial femoral artery disease. Results were sensitive to hypothesis on
number of stents and DEB used and their relative cost. CONCLUSIONS: PTA of
femoropopliteal arterial disease using DEB appears to be a clinical improvement for
treatment of PAD and a potentially cost saving strategy compared to use of stents
in the Italian Health Care System.
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OBJECTIVES: Cost-effectiveness analysis (CEA) of a medical test can require exten-
sive modeling if test results influence treatment decisions and disease progression.
We applied the assessment hierarchy of Schaafsma et al. (2009) to a CEA of a high
definition CT-scanner (one of the first assessments in the NICE/UK Diagnostics
Guidance Programme). METHODS: Schaafsma presents four steps to evaluate the
value of diagnostic tests: 1:accuracy assessment, 2:evaluation of added value,
3:clinical outcome assessment and 4:cost-effectiveness analysis. RESULTS: In the
assessment of diagnostic tests in coronary artery disease (CAD) modeling was
unavoidable, since a major problem in CEAs is the unavailability of randomized
controlled trials (RCT) that capture diagnosis, prognosis and treatment. Moreover,
most RCTs in the field of diagnostic test yield only information about sensitivity,
specificity, and short-term complication rates. When the evaluation is limited to
the added value of the high definition CT-scanner, one model, estimating the pro-
portions correctly diagnosed and complications associated with the CT-scanner, is
sufficient. However, since incorrect test results can result in major health loss
through incorrect or delayed treatment this method is inappropriate. Most tests
aim to improve prognosis thus, step 3 and 4 were applied in our assessment. There-
fore, five existing models were combined (diagnosis, CAD management, stroke
complication, radiation, non-CAD mortality) to create a meta-model that estimates
the cost-effectiveness. CONCLUSIONS: CEAs of a medical test can be performed in
various ways described by Schaafsma. If the aim is to conduct a comprehensive
analysis that includes various economic and health impacts, a synthesis of existing
models to create a meta-model is one way to achieve this. These models need to be
grafted together carefully to avoid invalid or irrelevant results; literature and ex-
pert opinion can assist in that endeavour. One critical pitfall is the use of models
created for dissimilar patient populations.
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ASSESSING COST EFFECTIVENESS AND VALUE OF FURTHER RESEARCH WHEN
DATA ARE SPARSE: NEGATIVE PRESSURE WOUND THERAPY FOR SEVERE
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OBJECTIVES:Health care resources are scarce and decisions have to be made about
how to allocate funds. Often these decisions are based on sparse or imperfect
evidence. One such example is negative pressure wound therapy (NPWT), which is
a widely used treatment for severe pressure ulcers; however, there is currently no
robust evidence that it is effective or cost effective.METHODS: This work considers
the decision to adopt NPWT given a range of alternative treatments, using a deci-
sion analytic modelling approach. Literature searches were conducted to identify
existing evidence on model parameters. Given the limited evidence base, a second
source of evidence, beliefs elicited from experts, was used. Judgements from ex-
perts on relevant (uncertain) quantities were obtained through a formal elicitation
exercise. Additionally, data derived from a pilot trial were also used to inform the
model. The three sources of evidence were collated, and the impact of each on cost
effectiveness was evaluated. RESULTS: Negative pressure wound therapy was ex-
pected to be less costly and more effective than any other treatments. The decision
to adopt NPWT was however very uncertain (probability of being cost effective of
0.55). The expected value of perfect information for the relevant UK population was
approximately £98 million. Specifically, the results suggest that a study evaluating
the effectiveness of NPWT might be worthwhile. The trial design that offered most
value was a three armed trial, with follow-up of at least 1 year and approximately
500 participants per arm. CONCLUSIONS: The analyses presented demonstrate
how allocation decisions about medical technologies can be explicitly informed
when data are sparse and, how this kind of analyses can be used to guide future
research prioritisation, not only indicating whether further research is worthwhile
but what type of research is needed and how it should be designed.
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OBJECTIVES: Nighttime urinary frequency (nocturia), common in patients with
overactive bladder (OAB), negatively impacts sleep quality. Three sleep-related
patient-reported questionnaires were assessed with regard to ability to discrimi-
nate between patients with and without OAB. METHODS: Adult men and women
with OAB symptoms for at least 3 months (8 micturitions per day;2 micturitions
per night; and6 urgency episodes over 3 days per bladder diary) and without OAB
symptoms (control group) completed several sleep questionnaires: Stanford Sleep-
iness Scale (morning and evening for 5 days), Epworth Sleepiness Scale, and Noc-
turia Quality of Life Questionnaire (N-QoL); t tests were performed between groups.
RESULTS: A total of 43 participants with OAB and 10 healthy controls were en-
rolled. Mean age and proportion of men were similar in the OAB and control groups
(63.7 vs. 55.6 years old [P0.31], and 46.2% vs 40.0% male [P0.53], respectively).
Race, employment status, and education level were also similar between groups
(all P0.25). Mean scores on the Stanford Sleepiness Scale across the 5 days were
significantly higher in the OAB group than the control group at time of awakening
(3.0 vs. 2.0; P0.0030) and at 7:00 pm (3.5 vs. 1.9; P0.0006), indicating greater
sleepiness. Epworth Sleepiness Scale mean scores were also significantly higher in
the OAB group than the control group (10.5 vs 4.1, respectively; P0.0001), indicat-
ing greater daytime sleepiness. On the N-QoL, participants with OAB had signifi-
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cantly lower mean Total scores than controls (54.7 vs. 99.2; P0.0001), Sleep/energy
scores (55.9 vs. 100.0; P0.0001), and Bother/concern scores (54.0 vs. 98.3; P0.0001),
indicating greater health-related quality of life impairment because of nighttime
urination. CONCLUSIONS: The Stanford Sleepiness Scale, Epworth Sleepiness
Scale, and N-QoL all effectively discriminate between participants with OAB symp-
toms and those without OAB symptoms.
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A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS CONDUCTED FOR
ASSESSMENT OF GENETIC TESTING TECHNOLOGIES
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OBJECTIVES: The conventional economic evaluations (EE) methods may be chal-
lenging within the context of genetic testing technologies (GTTs), because: the
main outcome a GTT is information, benefits may occur many years after taking
the test, non-medical harms might be associated with GTTs, and GTTs may also
provide information about the genetic status of the family members of affected
individuals. This study was performed to systematically review the methods used
in EEs included in Health Technology Assessments (HTAs) of GTTs. METHODS: A
systematic search of literature was undertaken to identify HTA reports on GTTs
that included EEs in addition to clinical effectiveness results. Studies were re-
viewed in terms of methods (e.g. type of EE, analytic perspective, cost-effectiveness
analysis), and quality (using QHES instrument).RESULTS:Of 342 identified citations,
13 HTAs consisting of 10 model-based and 3 trial-based EEs were included. More than
50% of the included studies had moderate to low quality scores mainly due to not
reporting information on basic elements of a standard EE and inadequate manage-
ment of uncertainty. Cost-effectiveness analysis (CEA) accounted for 62% of included
studies. 65% of the studies adopted a third party payer perspective, and 60% used a
lifelong time horizon. 75% of CEAs reported intermediate outcomes (e.g. cases-de-
tected). The majority of studies exclusively included technical costs of testing (100%)
and therapeutic or preventive interventions (62%). The most frequent variables tested
in univariate sensitivity analysis included costs (62%), effects (46%) and transition
probabilities (54%). Probabilistic sensitivity analysis was conducted in 31% of studies.
CONCLUSIONS: We found several methodological challenges in the reviewed EEs,
including: identification of a proper analytical perspective, inclusion of wider range
of outcomes and costs, allowing for long-term psychological, ethical and social
impacts of genetic tests, and sufficient management of uncertainty. These issues
should be carefully considered in future EEs of GTTs.
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SUPRAPUBIC TUBE PLACEMENT RELATED BOWEL INJURY: PROPOSED
GUIDELINES FOR OPEN PLACEMENT
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OBJECTIVES: Suprapubic catheterization (SPT) is a common urologic procedure
performed on an elective and urgent basis. Percutaneous approaches have devel-
oped in an effort to circumvent the need for general/spinal anesthesia, but are not
without risk. Rates of SPT-related bowel injury range from 0.3% to 2.7%. We expe-
rienced 4 cases and reviewed the literature to determine identifiable risk factors for
bowel injury.METHODS:A literature review was performed of all English language
articles listed in PubMed and articles reporting percutaneous SPT placement re-
lated bowel injury were selected. Included in our review are 4 cases in our institu-
tion. Data from articles and our cases was extracted to determine the technique of
SPT placement utilized, underlying risk factors, and nature of bowel injury.
RESULTS: Nineteen papers reported 22 cases of bowel injury as a result of percu-
taneous SPT placement, 2 of which were excluded for insufficient data. Addition-
ally, the 4 cases at our institution were included in the analysis. Small capacity or
thick-walled neurogenic bladders (4/24, 17%), prior abdominal surgery (13/24, 54%),
and pelvic radiation (5/24, 21%) were associated with bowel injury during SPT
placement. Diagnosis of bowel injury was based on history, physical examination
and imaging modalities. Bowel injury had a bimodal presentation, at initial place-
ment (14/24, 58%) and at initial SPT change (10/24, 42%). CONCLUSIONS: Based on
this review we advocate consideration of open SPT placement in patients with
small capacity or thick-walled neurogenic bladders, those in whom the bladder
cannot be distended adequately, prior abdominal/pelvic surgery or radiation, as-
cites. If percutaneous SPT is planned, Trendelenburg positioning and use of ultra-
sound and/or fluoroscopy at time of SPT placement is supported by the literature.
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COMPARISON OF SEIZURE AND HYDROCEPHALUS AND OTHER CLINICAL
CONDITIONS BEFORE AND AFTER SUBEPENDYMAL GIANT CELL
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OBJECTIVES: To compare the prevalence rates of seizure, hydrocephalus and other
clinical conditions before and after a surgical removal of subependymal giant cell
astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). METHODS:
A pre-post comparative longitudinal cohort study was conducted based on 3 large
US national healthcare claims databases (2000-2009). TSC patients with a first ob-
served SEGA surgery at age 35 or younger and with continuous health insurance
coverage 1 year before and 1 year after the surgery were selected. The prevalence
rates of seizure, hydrocephalus, and other TSC related clinical conditions, such as
vision disorders, coma, speechlessness, headache, stroke or hemiparesis, cognitive
difficulties, muscle weakness, papillodema, balance disorders, loss of sensation,
nausea and vomiting, depression, anxiety, attention deficit disorders, autism, and
sleep disorders, were estimated and compared between a period of the last 6 pre-
operative months and the first two postoperative periods (the 2nd to 6th postoper-
ative months; 7th to 12th postoperative months). Repeated measures analysis with
bootstrapping re-sampling approach was used for the cross-period comparisons.
RESULTS: The mean age of the select patients (N47) was 11.6 year at their first
observed SEGA surgery; the majority of the patients were male (66%). Statistically
significant postoperative increases in the prevalence rates of seizure (23 26%,
p0.05), hydrocephalus (2126%, p0.05), headache (1719%, p0.05), stroke and
hemiparesis (69%, p0.05), and autism (9%, p0.05) were observed.
CONCLUSIONS: This real-world claim data showed an increase in the risk of some
clinical conditions including seizure and hydrocephalus after a SEGA surgery in
patients with TSC. Further research to explore any possible causal relationship
between these risk increases and SEGA surgery through prospective studies or
registries is needed.
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RETROSPECTIVE COHORT STUDY
Sun P1, Liu Z2, Rogerio J2, Guo A2, Garay C2, Kohrman M3
1Kailo Research Group, Fishers, IN, USA, 2Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA, 3University of Chicago, Chicago, IL, USA
OBJECTIVES: To examine the prevalence rates of surgical complications among
tuberous sclerosis complex (TSC) patients with surgical removal of subpendymal
giant cell astrocytoma (SEGA). METHODS: Based on 3 US national health care
claims databases (20002009), a retrospective cohort study was conducted in TSC
patients who had a SEGA surgery at age 35 or younger, and were under continuous
health insurance coverage 1 year before and 1 year after the surgery. A SEGA sur-
gery was identified by a healthcare claim that simultaneously had a TSC diagnosis
code, a benign brain tumor diagnosis code and a procedure code of removing a
benign tumor from cerebral ventricle system. The surgical complications exam-
ined in the study included surgical procedure complications, nervous system com-
plications, surgical misadventures, postoperative infection, subdural empyemas,
and epidural abscess. The prevalence rates of these conditions were estimated for
the first postoperative year. RESULTS: Approximately 47 TSC patients had at least
one SEGA surgery. The mean age of patients at their 1st observed SEGA surgery was
11.6 years. The majority of patients (66%) were male. The prevalence rates of sur-
gical complications in the 1st postoperative year were 34% for surgical procedure
complications, 17% for subdural empyemas, 12.8% for nervous system complica-
tions, 6% for postoperative infection, 2% for epidural abscess, and 0% for surgical
misadventures respectively. CONCLUSIONS: In this real-world claim database
analysis, we observed that a portion of TSC patients experienced surgical compli-
cations within first year after their SEGA surgeries. Further research is needed to
better understand the causes of this surgical outcome.
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OBJECTIVES: To examine the postoperative prevalence of subependymal giant cell
astrocytoma (SEGA) diagnosis and repeated SEGA surgeries among patients with
tuberous sclerosis complex (TSC) who had an initial SEGA surgery. METHODS:
Based on three US national health claims databases (20002009), we conducted a
retrospective cohort study with TSC patients who had a first observed SEGA sur-
gery at age 35 or younger and were under continuous health insurance coverage 1
year before and 1 year after their 1st SEGA surgery. A SEGA surgery was defined as
having 1) a TSC diagnosis code, 2) a benign brain tumor diagnosis code, and 3) a
procedure code for removing a benign tumor from cerebral ventricle system. A
SEGA diagnosis is defined as 1) and 2). The prevalence rates of postoperative SEGA
diagnosis and repeated SEGA surgery were estimated for a period from the 3rd
through 6th postoperative month and a period from the 7th through 12th postoper-
ative month respectively. RESULTS: The select patients (N47) had mean age of
11.6 years (at the 1st SEGA surgery) with 66% males. After the 1st observed SEGA
surgery, postoperative prevalence rates of SEGA diagnosis was 34% in the period
from the 3rd to 6th postoperative month and 26% in the period from the 7th to 12th
postoperative month. About 49% patients had a repeated SEGA surgery in their 1st
postoperative year. CONCLUSIONS: In the real-world setting, TSC patients with
SEGA surgery may experience repeated SEGA surgeries or/and still have SEGA di-
agnoses within the first postoperative year. Further research on the effectiveness
of SEGA surgery via prospective studies or registries is needed to improve care in
TSC patients with SEGA.
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